Industries > Life Sciences & Healthcare > Opportunity Identification, Assessment, and Prioritization

Opportunity Identification, Assessment, and Prioritization

An amalgamation of strategic and market evaluation and competitive intelligence (CI) for pharma, devices, diagnostics, and other life sciences and diagnostics companies that are planning to introduce or optimize the presence of products amid the market competition and price war.

Blogs | Increasing AI/ML Footprint in Life Sciences and Healthcare

Why Is a Strategic Opportunity Assessment, Identification, and Prioritization Plan Imperative for Your Business?

Life Sciences & Healthcare market entry or penetration involves assessment of market nuances and reality checks, before any product entry decision, pricing adjustment, product positioning, or strategic initiatives in response to competitive situation.

We help you address these questions before you plan the process.

  • What is the current size of the market opportunity for me and how it is likely to grow or decline in the future?
  • How do I use... Read More
Strategic Opportunity Assessment

What We Offer

SGA covers both native English-speaking and non-English-speaking markets like the GCC, CIS, SEA, and LATAM.

SGA offers a 360° overview of healthcare and market access systems and tracks how the key country pricing systems work before planning your market entry or expansion.

SGA measures the strength of your clinical profile and the ‘pricing power’ it affords you by conducting market surveys and primary research with the end users.

SGA uses evidence-based techniques to get the most accurate feedback while conducting pricing research with the stakeholders. Our insights are stronger and better as our pool size of customer interviewees is statistically significant and driven by our in-house panelists.

SGA analyzes historic payer behavior and current nuances as a powerful predictor and explainer of future pricing behavior. Our forecast models are customizable and data-driven and built by industry experts with over 15 years of experience in their specific fields.

SGA’s global network helps you evaluate the impact of your product’s prices globally.

Our team of experts supports your market access teams during the implementation phase and helps build a sustainable near-term roadmap.


Industry Leaders

SGA thrives by its brand promise Lifes Possible and is recognized as the trusted life sciences & healthcare business consulting and services provider company in the U.S.

12+ Languages

Multilingual capabilities include Mandarin, Cantonese, Korean, German, Spanish, Arabic, Bahasa, Hindi, Bengali, and English (U.S. & U.K.) experts (either in-house or partnerships).

Data-Driven Insights

With in-depth domain knowledge and proven capabilities of delivering monetizable insights, we deliver high-quality, efficient outputs.

End-To-End Solutioning

The in-house KOL capability of more than 700, along with in-house capabilities of primary market research, financial research, data analytics, engineering, IT, and ESG research and consulting, helps to present credible competitive information.

Who We Work With


SG Analytics - Healthcare - Whitepaper - Emergence of Novel Immune-Mediated Therapies


Emergence of Novel Immune - Mediated Therapies

Immunotherapy has emerged as a promising treatment for cancer, with immune checkpoint inhibitors (ICIs) dominating the market. The market is projected to...

Technological  Advancements


Future Trends and Technological Advances in Vaccine and Disease Prevention

The introduction of vaccines for key diseases, such as meningococcal meningitis A, hepatitis E, and malaria, in recent years has helped to reduce mortality...

SGA Whitepaper Market Entry in 2023


Market Entry in 2023: Why Must You Also Look at Markets Other Than the US and Japan?

Due to dollar fluctuations and the likelihood of market recession, investors and manufacturers of medical devices and pharma are exploring new opportunities...

We strongly believe in equal opportunity for all. Our research team consists of more females than males i.e., 55 % females, and consists of PhDs, M Pharms, D Pharms, Postgraduate in finance, Biotech postgraduates, and MBAs.

Our combined experience of pharmaceuticals, medical devices, life sciences, and med-tech ensures high-quality, white-labelled research coverage.